Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.MedImmune and the University of Texas MD Anderson Cancer Center have entered into a three-year translational and clinical research collaboration to study therapies that unleash patients’ immune systems to attack their cancers through MD Anderson’s Moon Shots Program.
Subscribe to our email newsletter
MD Anderson’s Moon Shots Program would help in reducing cancer deaths by targeting eight cancers with the support of several new research platforms that provide infrastructure, expertise and technology.
The company is conducting clinical trials using a new therapeutic paradigm that targets immune cells to improve their tumor-fighting ability, rather than targeting the tumor cell itself.
As part of the deal, MD Anderson will assess several of MedImmune’s immunotherapy molecules in a clinical setting to better understand how these molecules elicit immune response in patients.
MedImmune senior vice president and head of Oncology Innovative Medicines Unit Ed Bradley said the company is excited to work with MD Anderson in the Moon Shots program, pairing their unique immunotherapy platform with our innovative portfolio of immune-mediated cancer therapies.
"Our partnership will provide MedImmune with an invaluable opportunity to evaluate the biological impact of our immune-mediated cancer agents, both as monotherapy and combination therapy," Ed Bradley said.